Ixekizumab for treatment of psoriasis

Dyring‐Andersen, Beatrice; Skov, Lone; Zachariae, Claus

doi:10.1586/1744666x.2015.1023295

Cited by 10 publications

(8 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pro-inflammatory cytokine IL-17 is recognized as playing an important role in the pathogenesis of psoriasis, an inflammatory skin disease, and the relevance of the IL-23/IL-17 axis is underlined by the recent clinical efficacy of treatments targeting this axis 1 .…”

Section: To the Editormentioning

confidence: 99%

Interleukin (IL)-17A and IL-22-producing neutrophils in psoriatic skin

et al. 2017

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 99%

Interleukin (IL)-17A and IL-22-producing neutrophils in psoriatic skin

et al. 2017

View full text Add to dashboard Cite

“…Several human monoclonal antibodies directed against IL-17 are in development, including brodalumab (AMG 827), ixekizumab (LY2439821), and secukinumab (Cosentyx; Novartis, Basel, Switzerland). Clinical development of these humanized monoclonal antibodies has focused on psoriasis, where they have been shown to be effective [132,133]. The contribution of IL-6 in MG is suggested by its activity as a promoter of B-cell differentiation and proliferation and in the induction of B-cell maturation into antibody-producing plasma cells [134].…”

Section: Cytokine Cytokine Receptors and Growth Factorsmentioning

confidence: 99%

Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis

2016

View full text Add to dashboard Cite

Myasthenia gravis (MG) is an autoimmune disease associated with the production of autoantibodies against 1) the skeletal muscle acetylcholine receptor; 2) muscle-specific kinase, a receptor tyrosine kinase critical for the maintenance of neuromuscular synapses; 3) low-density lipoprotein receptor-related protein 4, an important molecular binding partner for muscle-specific kinase; and 4) other muscle endplate proteins. In addition to the profile of autoantibodies, MG may be classified according the location of the affected muscles (ocular vs generalized), the age of symptom onset, and the nature of thymic pathology. Immunopathologic events leading to the production of autoantibodies differ in the various disease subtypes. Advances in our knowledge of the immunopathogenesis of the subtypes of MG will allow for directed utilization of the ever-growing repertoire of therapeutic agents that target distinct nodes in the immune pathway relevant to the initiation and maintenance of autoimmune disease. In this review, we examine the pathogenesis of MG subtypes, current treatment options, and emerging new treatments and therapeutic targets.

show abstract

“…Ixekizumab has proved to be significantly more effective than the soluble anti-TNF-α receptor in clearing plaque-type psoriasis with effects that are maintained in time 40,49,51,52…”

Section: Introductionmentioning

confidence: 99%

“…It is difficult to estabilish an algorithm for sequential treatment in psoriasis patients since there are limited data on the efficacy of an anti-IL-17 agent in patients experiencing anti-TNF-alpha failure in real life 52,53. Nevertheless, currently available phase I–III data indicate that ixekizumab is a promising drug, although long-term data on the efficacy and safety and real-world data are needed before ixekizumab and other IL-17-targeting agents can find their place in clinical practice 49,52…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy

Giunta¹,

Ventura²,

Chimenti

et al. 2017

DDDT

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory disease affecting up to 3% of the general population, associated with discomfort and impaired quality of life. In recent years, the pathogenic cytokine network of psoriasis has been extensively studied leading to the development of new treatments that provide greater efficacy. Interleukin 17A (IL-17A) has been recognized as a crucial cytokine that mediates immunopathogenesis of psoriasis. Ixekizumab – indicated for the treatment of adults with moderate-to-severe plaque psoriasis – is a subcutaneously administered humanized monoclonal antibody that targets IL-17A. A large percentage of patients affected by psoriasis achieved consistent benefits in terms of disease control and rapid onset of action during clinical trials. Overall, ixekizumab brought clinical improvement and a favorable safety profile in phase III trials. Ixekizumab is characterized by consistent efficacy and rapid onset of response; it is not influenced by previous exposure to biologics and has shown good results in areas that are difficult to treat and in severe clinical variants of psoriasis. Ixekizumab has shown significant improvements in the activity of the disease and in those physical functions that inhibit radiographic progression in patients with concomitant involvement of joints. Our data support ixekizumab as a successful therapeutic option for patients affected by moderate-to-severe plaque-type psoriasis.

show abstract

Ixekizumab for treatment of psoriasis

Cited by 10 publications

References 47 publications

Interleukin (IL)-17A and IL-22-producing neutrophils in psoriatic skin

Interleukin (IL)-17A and IL-22-producing neutrophils in psoriatic skin

Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy

Contact Info

Product

Resources

About